ADARx Pharmaceuticals (NASDAQ:ADRX) Stock: Insider Erez Chimovits Buys 61,516 Shares

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) Director Erez Chimovits bought 61,516 shares of the company’s stock in a transaction that occurred on Monday, September 28th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $1,045,772.00. Following the completion of the purchase, the director owned 9,292,025 shares in the company, valued at $157,964,425. The trade was a 0.67% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ADARx Pharmaceuticals Trading Down 3.4%

ADARx Pharmaceuticals stock traded down $0.70 during midday trading on Wednesday, reaching $19.94. The company’s stock had a trading volume of 788,778 shares, compared to its average volume of 1,097,539. ADARx Pharmaceuticals, Inc. has a 52-week low of $18.50 and a 52-week high of $23.21.

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based medicines for immune-mediated and other serious diseases. The company is headquartered in San Diego, California, and uses proprietary technologies designed to modulate disease-related proteins at the RNA level.

ADARx’s pipeline includes investigational therapies intended to address conditions involving the complement system, coagulation pathways and other biologic mechanisms. Its programs are designed to provide targeted, durable treatment through approaches such as RNA interference and related forms of RNA-based therapeutic intervention.

Founded in 2018, ADARx has advanced its drug candidates through preclinical and clinical development and has pursued regulatory and clinical activities in the United States and other international markets.